{"hands_on_practices": [{"introduction": "Signaling begins at the cell surface with a \"molecular handshake\" between a ligand and its receptors. This initial interaction is not a simple on/off switch; it is a quantitative process governed by the laws of mass action, where receptor numbers and ligand concentration determine the strength of the initial signal. This practice [@problem_id:2683637] challenges you to apply fundamental principles of chemical kinetics to calculate receptor occupancy and determine which components may be limiting, providing a crucial quantitative foundation for understanding how cells first interpret extracellular cues.", "problem": "A dimeric ligand of the Transforming Growth Factor beta (TGF-β) superfamily, such as Activin A, signals by assembling heteromeric complexes of type I and type II serine/threonine kinase receptors at the cell surface. Consider a single cell expressing a total of $5{,}000$ type I receptors and $10{,}000$ type II receptors on its plasma membrane. The extracellular ligand concentration is $0.5$ nM, and the apparent dissociation constant ($K_d$) for ligand binding to either receptor subtype in isolation is $1$ nM. Assume the following: (i) the system is at steady state, (ii) ligand is not appreciably depleted by binding to this cell so that the free ligand concentration remains equal to the bulk concentration, (iii) each receptor binds ligand monovalently with the same apparent $K_d$, and (iv) a signaling-competent complex requires $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors per ligand dimer (a heterotetramer).\n\nStarting from the law of mass action for a reversible binding reaction $R + L \\rightleftharpoons RL$ and the definition $K_d = \\frac{[R][L]}{[RL]}$, derive the equilibrium fractional occupancy for a receptor pool at ligand concentration $[L]$. Use this to estimate the fractional occupancy of each receptor subtype at $[L] = 0.5$ nM and $K_d = 1$ nM. Compute the expected numbers of ligand-bound type I and type II receptors on the cell. Identify which receptor subtype is limiting for assembly of heterotetrameric signaling complexes, given the 2:2 stoichiometry. Finally, report the expected number of signaling-competent heterotetrameric complexes per cell implied by these occupancies.\n\nRound your final numeric answer to four significant figures. Express the final answer as a pure number (no units).", "solution": "The problem requires a quantitative analysis of receptor-ligand interactions and subsequent complex formation based on the law of mass action. The validity of the problem statement must first be established.\n\n**Problem Validation:**\nThe explicit givens are:\nTotal number of type I receptors, $N_{R_I, tot} = 5000$.\nTotal number of type II receptors, $N_{R_{II}, tot} = 10000$.\nLigand concentration, $[L] = 0.5$ nM.\nDissociation constant for ligand binding to either receptor, $K_d = 1$ nM.\nAssumptions: (i) the system is at steady state; (ii) free ligand concentration $[L]$ is constant and equal to the bulk concentration; (iii) each receptor binds the ligand dimer via a monovalent interaction described by the given $K_d$; (iv) a signaling-competent complex requires $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors per ligand dimer.\n\nThe problem is scientifically grounded in fundamental principles of chemical kinetics and receptor theory. The parameter values are biologically plausible. The problem is well-posed, providing sufficient information to determine a unique solution. The assumptions, while simplifying the true multi-step, cooperative nature of TGF-$\\beta$ receptor complex assembly, are explicitly stated and create a self-consistent, tractable mathematical model. Such simplifications are standard in biophysical modeling for pedagogical purposes. The problem is therefore deemed valid.\n\n**Step 1: Derivation of the Fractional Occupancy Equation**\nWe start from the reversible binding reaction for a receptor $R$ and a ligand $L$:\n$$ R + L \\rightleftharpoons RL $$\nThe dissociation constant, $K_d$, is defined by the concentrations at equilibrium:\n$$ K_d = \\frac{[R][L]}{[RL]} $$\nHere, $[R]$ is the concentration of free receptor, $[L]$ is the concentration of free ligand, and $[RL]$ is the concentration of the receptor-ligand complex. The total concentration of receptors, $[R_{tot}]$, is the sum of the free and bound forms:\n$$ [R_{tot}] = [R] + [RL] $$\nThe fractional occupancy, $\\theta$, is the fraction of total receptors that are ligand-bound:\n$$ \\theta = \\frac{[RL]}{[R_{tot}]} $$\nTo express $\\theta$ as a function of $[L]$ and $K_d$, we first rearrange the $K_d$ expression to solve for $[R]$:\n$$ [R] = \\frac{K_d [RL]}{[L]} $$\nWe substitute this into the equation for the total receptor concentration:\n$$ [R_{tot}] = \\frac{K_d [RL]}{[L]} + [RL] = [RL] \\left( \\frac{K_d}{[L]} + 1 \\right) = [RL] \\left( \\frac{K_d + [L]}{[L]} \\right) $$\nBy rearranging this result, we can solve for the ratio $\\frac{[RL]}{[R_{tot}]}$, which is the fractional occupancy $\\theta$:\n$$ \\theta = \\frac{[L]}{K_d + [L]} $$\nThis is the required expression for fractional occupancy.\n\n**Step 2: Calculation of Receptor Occupancies and Numbers of Bound Receptors**\nThe problem states that the ligand concentration is $[L] = 0.5$ nM and the dissociation constant is $K_d = 1$ nM. Since both type I ($R_I$) and type II ($R_{II}$) receptors are assumed to bind the ligand with the same $K_d$, their fractional occupancies, $\\theta_I$ and $\\theta_{II}$, will be identical.\n$$ \\theta_I = \\theta_{II} = \\frac{[L]}{K_d + [L]} = \\frac{0.5}{1 + 0.5} = \\frac{0.5}{1.5} = \\frac{1}{3} $$\nThus, at steady state, one-third of all receptors of each type are expected to be bound to a ligand.\n\nNext, we calculate the expected number of ligand-bound receptors for each subtype on the cell surface.\nThe total number of type I receptors is $N_{R_I, tot} = 5000$. The expected number of ligand-bound type I receptors, $N_{R_I L}$, is:\n$$ N_{R_I L} = N_{R_I, tot} \\times \\theta_I = 5000 \\times \\frac{1}{3} = \\frac{5000}{3} $$\nThe total number of type II receptors is $N_{R_{II}, tot} = 10000$. The expected number of ligand-bound type II receptors, $N_{R_{II} L}$, is:\n$$ N_{R_{II} L} = N_{R_{II}, tot} \\times \\theta_{II} = 10000 \\times \\frac{1}{3} = \\frac{10000}{3} $$\n\n**Step 3: Identification of Limiting Receptor and Calculation of Signaling Complexes**\nA signaling-competent complex requires a stoichiometry of $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors. We must determine the maximum number of such heterotetrameric complexes, $N_c$, that can be assembled from the available pools of bound receptors. This is a problem of a limiting reactant.\n\nThe number of complexes is limited by the component that is exhausted first. We can calculate the maximum number of complexes that could be formed given the number of bound receptors of each type.\nThe number of complexes supportable by the pool of bound type I receptors is the number of available bound receptors divided by the stoichiometry per complex ($2$):\n$$ N_{c,max,I} = \\frac{N_{R_I L}}{2} = \\frac{5000/3}{2} = \\frac{5000}{6} = \\frac{2500}{3} $$\nSimilarly, the number of complexes supportable by the pool of bound type II receptors is:\n$$ N_{c,max,II} = \\frac{N_{R_{II} L}}{2} = \\frac{10000/3}{2} = \\frac{10000}{6} = \\frac{5000}{3} $$\nThe expected number of complexes that can actually form, $N_c$, is the minimum of these two capacities:\n$$ N_c = \\min(N_{c,max,I}, N_{c,max,II}) = \\min\\left(\\frac{2500}{3}, \\frac{5000}{3}\\right) = \\frac{2500}{3} $$\nBecause $N_{c,max,I}  N_{c,max,II}$, the formation of signaling complexes is limited by the availability of ligand-bound type I receptors. Thus, the type I receptor is the limiting subtype in this system.\n\nFinally, we express the expected number of signaling complexes as a numerical value, rounded to four significant figures as requested.\n$$ N_c = \\frac{2500}{3} \\approx 833.333... $$\nRounding this value to four significant figures gives $833.3$. This represents the expected number of signaling-competent heterotetrameric complexes per cell under the given conditions and modeling assumptions.", "answer": "$$\\boxed{833.3}$$", "id": "2683637"}, {"introduction": "Once a receptor complex is activated, it must relay the signal to the correct intracellular pathway. The TGF-β superfamily exemplifies this specificity, with different ligands triggering distinct Smad pathways to control different cellular fates. This thought experiment [@problem_id:2683687] delves into the molecular basis of this choice, focusing on how specific protein domains, like the L45 loop, act as critical docking sites that dictate substrate selection, effectively routing the signal to the correct downstream effectors.", "problem": "A central question in Transforming Growth Factor Beta (TGF-β) superfamily signaling is how type I receptors choose which receptor-regulated Smads (R-Smads) to phosphorylate. Consider the following well-established base:\n\n- Canonical TGF-β superfamily signaling proceeds when a dimeric ligand brings together type II and type I serine/threonine kinase receptors. The type II receptor phosphorylates the glycine-serine-rich (GS) domain of the type I receptor, activating its kinase. The activated type I receptor then phosphorylates R-Smads on their C-terminal Ser-Ser-X-Ser motif. R-Smads segregate into two classes: the Activin/Nodal/TGF-β branch signals primarily through Smad2/3 via type I receptors such as Activin receptor-like kinase (ALK)4, ALK5, and ALK7, whereas the Bone Morphogenetic Protein (BMP) branch signals primarily through Smad1/5/8 via type I receptors such as ALK1, ALK2, ALK3, and ALK6.\n- Specificity of R-Smad recruitment and phosphorylation is encoded by complementary docking surfaces: a short surface-exposed sequence on the type I receptor kinase domain known as the L45 loop, and the Mad Homology 2 (MH2) L3 loop on R-Smads. The L45 loop differs between Activin/TGF-β-class receptors and BMP-class receptors and mediates selective binding to Smad2/3 versus Smad1/5/8, respectively.\n\nYou engineer two chimeric type I receptors in which only the L45 loop is swapped:\n- Chimera A: ALK4 in which the native L45 loop is replaced by the L45 loop sequence from ALK6.\n- Chimera B: ALK6 in which the native L45 loop is replaced by the L45 loop sequence from ALK4.\n\nAll other receptor features (ligand-binding cooperation with appropriate type II receptors, GS domain, kinase active site, juxtamembrane regions) are intact and unaltered, and cells express the relevant type II receptors for both Activin and BMP ligands. You stimulate cells expressing each chimera separately with saturating Activin A or BMP7 and assay C-terminal phosphorylation and nuclear accumulation of Smad2/3 and Smad1/5/8.\n\nWhich prediction best follows from the base principles above regarding how the L45 loop dictates R-Smad specificity?\n\nA. Swapping the L45 loops will invert R-Smad specificity: ALK4(L45 from ALK6) will recruit and phosphorylate Smad1/5/8 in response to Activin A, and ALK6(L45 from ALK4) will recruit and phosphorylate Smad2/3 in response to BMP7, with minimal phosphorylation of the noncognate R-Smad class in each case.\n\nB. Swapping the L45 loops will have no effect on R-Smad specificity because the catalytic cleft of the kinase dictates substrate choice; ALK4 will continue to phosphorylate Smad2/3 and ALK6 will continue to phosphorylate Smad1/5/8 regardless of the L45 loop.\n\nC. Swapping the L45 loops will abolish signaling by disrupting GS domain phosphorylation, preventing any R-Smad phosphorylation even in the presence of ligand.\n\nD. Swapping the L45 loops will render both receptors promiscuous, leading to robust phosphorylation of both Smad2/3 and Smad1/5/8 by each chimera irrespective of which ligand is applied.", "solution": "The problem statement must first be validated for scientific and logical integrity.\n\n### Step 1: Extract Givens\nThe problem statement provides the following information:\n1.  **Canonical Signaling Pathway**: Transforming Growth Factor Beta (TGF-β) superfamily signaling is initiated by a dimeric ligand binding to a complex of type II and type I serine/threonine kinase receptors.\n2.  **Activation Mechanism**: The type II receptor phosphorylates the glycine-serine-rich (GS) domain of the type I receptor, which activates the type I receptor kinase.\n3.  **Substrate Phosphorylation**: The activated type I receptor phosphorylates Receptor-Regulated Smads (R-Smads) on a C-terminal `Ser-Ser-X-Ser` motif.\n4.  **Signaling Branches**: There are two primary R-Smad branches:\n    *   The Activin/Nodal/TGF-β branch utilizes `Smad2/3` and is mediated by type I receptors `ALK4`, `ALK5`, and `ALK7`.\n    *   The Bone Morphogenetic Protein (BMP) branch utilizes `Smad1/5/8` and is mediated by type I receptors `ALK1`, `ALK2`, `ALK3`, and `ALK6`.\n5.  **Specificity Determinant**: The specificity of R-Smad phosphorylation is determined by the interaction between the `L45` loop of the type I receptor kinase domain and the Mad Homology 2 (MH2) `L3` loop on the R-Smad. This interaction is described as selective binding via complementary docking surfaces.\n6.  **Chimeric Constructs**: Two chimeric receptors are engineered:\n    *   Chimera A: `ALK4` with its native `L45` loop replaced by the `L45` loop from `ALK6`.\n    *   Chimera B: `ALK6` with its native `L45` loop replaced by the `L45` loop from `ALK4`.\n7.  **Experimental Conditions**: All other receptor domains are unaltered. Cells express necessary type II receptors. Stimulation is performed with saturating concentrations of either `Activin A` or `BMP7`. The assay measures C-terminal phosphorylation and nuclear accumulation of `Smad2/3` and `Smad1/5/8`.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n*   **Scientifically Grounded**: The problem statement accurately describes the established principles of TGF-β superfamily signaling. The roles of the receptors (`ALK4`, `ALK6`), ligands (`Activin A`, `BMP7`), R-Smads (`Smad2/3`, `Smad1/5/8`), and the `L45` loop as a key specificity determinant are consistent with current knowledge in molecular and developmental biology.\n*   **Well-Posed**: The problem is clearly structured. It presents a set of established principles and a hypothetical experiment (a domain-swap), then asks for a logical prediction based on those principles. The setup is self-contained and sufficient information is provided to deduce a unique answer.\n*   **Objective**: The language is precise and technical, free of subjectivity or ambiguity.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, formally structured, and requires logical deduction from given premises.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation of the Correct Answer\n\nThe solution is deduced by applying the given principles to the two engineered chimeras. The central premise is that ligand specificity is endowed by the receptor's extracellular domain (part of the main receptor \"body\"), while R-Smad substrate specificity is endowed by the `L45` loop of the intracellular kinase domain.\n\n**Analysis of Chimera A: `ALK4`(L45 from `ALK6`)**\n1.  **Ligand Recognition and Activation**: The body of this receptor is `ALK4`. `ALK4` is an Activin-type receptor. Therefore, it will be activated by its cognate ligand, `Activin A`, in conjunction with the appropriate type II receptor. It will not be activated by `BMP7`, which is a BMP-type ligand. Upon binding `Activin A`, the associated type II receptor will phosphorylate the intact GS domain of Chimera A, activating its kinase.\n2.  **R-Smad Recruitment and Phosphorylation**: The `L45` loop of Chimera A is from `ALK6`. `ALK6` is a BMP-type receptor whose `L45` loop selectively recruits `Smad1/5/8`. Therefore, the activated kinase of Chimera A will recruit and phosphorylate `Smad1/5/8`, not its native substrate `Smad2/3`.\n3.  **Predicted Outcome for Chimera A**: Stimulation with `Activin A` will lead to phosphorylation of `Smad1/5/8`. Stimulation with `BMP7` will produce no signaling through this chimera.\n\n**Analysis of Chimera B: `ALK6`(L45 from `ALK4`)**\n1.  **Ligand Recognition and Activation**: The body of this receptor is `ALK6`. `ALK6` is a BMP-type receptor. It will be activated by its cognate ligand, `BMP7`. It will not be activated by `Activin A`. Upon binding `BMP7`, the associated type II receptor will phosphorylate the intact GS domain of Chimera B, activating its kinase.\n2.  **R-Smad Recruitment and Phosphorylation**: The `L45` loop of Chimera B is from `ALK4`. `ALK4` is an Activin-type receptor whose `L45` loop selectively recruits `Smad2/3`. Therefore, the activated kinase of Chimera B will recruit and phosphorylate `Smad2/3`, not its native substrate `Smad1/5/8`.\n3.  **Predicted Outcome for Chimera B**: Stimulation with `BMP7` will lead to phosphorylation of `Smad2/3`. Stimulation with `Activin A` will produce no signaling through this chimera.\n\nIn summary, the swap of the `L45` loop inverts the R-Smad specificity of each receptor while preserving its original ligand specificity.\n\n### Option-by-Option Analysis\n\n**A. Swapping the L45 loops will invert R-Smad specificity: ALK4(L45 from ALK6) will recruit and phosphorylate Smad1/5/8 in response to Activin A, and ALK6(L45 from ALK4) will recruit and phosphorylate Smad2/3 in response to BMP7, with minimal phosphorylation of the noncognate R-Smad class in each case.**\nThis option aligns perfectly with our derivation. `Activin A` activates the `ALK4` body, which then uses the `ALK6` `L45` loop to phosphorylate `Smad1/5/8`. `BMP7` activates the `ALK6` body, which then uses the `ALK4` `L45` loop to phosphorylate `Smad2/3`. This is a direct consequence of the principles stated in the problem.\n**Verdict: Correct.**\n\n**B. Swapping the L45 loops will have no effect on R-Smad specificity because the catalytic cleft of the kinase dictates substrate choice; ALK4 will continue to phosphorylate Smad2/3 and ALK6 will continue to phosphorylate Smad1/5/8 regardless of the L45 loop.**\nThis option contradicts a fundamental premise of the problem: that \"Specificity of R-Smad recruitment and phosphorylation is encoded by... the L45 loop\". It proposes an alternative mechanism for specificity (the catalytic cleft) that is not supported by the given information.\n**Verdict: Incorrect.**\n\n**C. Swapping the L45 loops will abolish signaling by disrupting GS domain phosphorylation, preventing any R-Smad phosphorylation even in the presence of ligand.**\nThis is factually incorrect based on the problem description. The `L45` loop is part of the kinase domain, which is spatially and functionally distinct from the juxtamembrane GS domain. The problem explicitly states the GS domain is \"intact and unaltered\". Activation of the kinase via GS domain phosphorylation by the type II receptor should proceed normally.\n**Verdict: Incorrect.**\n\n**D. Swapping the L45 loops will render both receptors promiscuous, leading to robust phosphorylation of both Smad2/3 and Smad1/5/8 by each chimera irrespective of which ligand is applied.**\nThis option contains two errors. First, it negates the principle of selective binding mediated by the `L45` loop, incorrectly predicting promiscuity instead of a shift in specificity. Second, it incorrectly claims signaling will occur \"irrespective of which ligand is applied,\" ignoring that ligand specificity is determined by the receptor's extracellular domain, which was not swapped. `ALK4` will still only respond to Activin-type ligands, and `ALK6` will still only respond to BMP-type ligands.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2683687"}, {"introduction": "The developmental impact of signaling pathways like BMP often extends beyond a single cell, creating spatial patterns across an entire tissue. This is achieved through the formation of morphogen gradients, where concentration thresholds of a signaling molecule instruct cells to adopt different fates based on their position. This exercise [@problem_id:2683698] invites you to model this process, deriving the characteristic length scale of a gradient from a reaction-diffusion equation and connecting molecular parameters like diffusion ($D$) and degradation ($k$) to macroscopic, tissue-level patterns.", "problem": "A Bone Morphogenetic Protein (BMP) morphogen from the Transforming Growth Factor beta (TGF-$\\beta$) superfamily forms a one-dimensional steady-state gradient in embryonic tissue. Consider an effectively semi-infinite domain $x \\ge 0$, with the source at $x=0$ supplying BMP at a constant flux and with uniform first-order removal (e.g., receptor-mediated internalization or extracellular degradation) throughout the tissue. The BMP concentration $C(x,t)$ obeys the reaction-diffusion equation based on Fickian diffusion and first-order decay: $\\frac{\\partial C}{\\partial t} = D \\frac{\\partial^{2} C}{\\partial x^{2}} - k C$, where $D$ is the diffusion coefficient and $k$ is the first-order removal rate constant. At steady state, the profile $C(x)$ remains finite as $x \\to \\infty$.\n\n- Starting from these principles, derive the general steady-state spatial profile and identify the characteristic decay length of the morphogen gradient as a function of $D$ and $k$. Do not assume any specific formula for the decay length a priori; derive it from the differential equation and the boundary condition at infinity.\n\n- Then, using $D = 10$ $\\mu\\mathrm{m}^{2}/\\mathrm{s}$ and $k = 0.001$ $\\mathrm{s}^{-1}$, compute the numerical value of this characteristic decay length. Round your answer to three significant figures and express it in micrometers.", "solution": "The problem statement is submitted for validation.\n\nFirst, we extract the given information verbatim.\n- **System**: A one-dimensional steady-state morphogen gradient of Bone Morphogenetic Protein (BMP) from the Transforming Growth Factor beta (TGF-$\\beta$) superfamily.\n- **Domain**: An effectively semi-infinite domain $x \\ge 0$.\n- **Source**: Located at $x=0$, supplying BMP at a constant flux.\n- **Removal Mechanism**: Uniform first-order removal throughout the tissue, with rate constant $k$.\n- **Governing Equation**: The reaction-diffusion equation for BMP concentration $C(x,t)$ is given as $\\frac{\\partial C}{\\partial t} = D \\frac{\\partial^{2} C}{\\partial x^{2}} - k C$.\n- **Constants**: $D$ is the diffusion coefficient, and $k$ is the first-order removal rate constant.\n- **Boundary Condition**: At steady state, the concentration profile $C(x)$ remains finite as $x \\to \\infty$.\n- **Numerical Values**: $D = 10$ $\\mu\\mathrm{m}^{2}/\\mathrm{s}$ and $k = 0.001$ $\\mathrm{s}^{-1}$.\n- **Tasks**:\n    1. Derive the general steady-state spatial profile and the characteristic decay length as a function of $D$ and $k$.\n    2. Compute the numerical value of this characteristic decay length, rounded to three significant figures.\n\nNow, we validate the problem based on these extracted givens.\n1.  **Scientific Grounding**: The problem is grounded in the established field of developmental biology and mathematical modeling. The reaction-diffusion equation is a standard, fundamental model for describing morphogen gradient formation. BMPs are well-established morphogens. The model is scientifically sound and does not violate any fundamental principles.\n2.  **Well-Posedness**: The problem describes a second-order ordinary differential equation (at steady state) with two boundary conditions: a constant flux at $x=0$ (a Neumann boundary condition) and a finite concentration at $x \\to \\infty$. This setup is well-posed and leads to a unique, meaningful solution for the concentration profile.\n3.  **Objectivity**: The problem is stated in precise, quantitative, and objective language, free of subjective or ambiguous terminology.\n4.  **Completeness**: The problem provides all necessary information to derive the characteristic decay length, which depends only on the parameters $D$ and $k$ and is independent of the specific flux value at the source.\n\nThe verdict of this validation is that the problem is **valid**. It is a standard, well-posed problem in mathematical biology. We proceed with the solution.\n\nThe governing partial differential equation for the concentration $C(x, t)$ is:\n$$\n\\frac{\\partial C}{\\partial t} = D \\frac{\\partial^{2} C}{\\partial x^{2}} - k C\n$$\nAt steady state, the concentration profile no longer changes with time, which means $\\frac{\\partial C}{\\partial t} = 0$. The equation simplifies to a second-order ordinary differential equation (ODE) for the spatial profile $C(x)$:\n$$\nD \\frac{d^{2} C}{d x^{2}} - k C = 0\n$$\nThis can be rearranged into a standard form:\n$$\n\\frac{d^{2} C}{d x^{2}} - \\frac{k}{D} C = 0\n$$\nThis is a linear, homogeneous ODE with constant coefficients. We seek a solution by assuming the form $C(x) = \\exp(rx)$. Substituting this into the ODE yields the characteristic equation:\n$$\nr^{2} - \\frac{k}{D} = 0\n$$\nThe roots of this equation are $r_{1,2} = \\pm\\sqrt{\\frac{k}{D}}$. The general solution for $C(x)$ is a linear combination of the two independent solutions:\n$$\nC(x) = A_1 \\exp\\left(\\sqrt{\\frac{k}{D}} x\\right) + A_2 \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nwhere $A_1$ and $A_2$ are integration constants determined by the boundary conditions.\n\nThe problem states that the concentration $C(x)$ must remain finite as $x \\to \\infty$. Let us examine the two terms in the general solution.\nThe first term, $A_1 \\exp\\left(\\sqrt{\\frac{k}{D}} x\\right)$, grows exponentially and diverges to infinity as $x \\to \\infty$, since $k$ and $D$ are positive physical constants. For the total concentration to remain finite, the coefficient of this term must be zero. Therefore, we must have $A_1 = 0$.\nThis leaves us with the solution:\n$$\nC(x) = A_2 \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nThis function describes an exponential decay from the source at $x=0$. The characteristic decay length, which we denote by $\\lambda$, is the length scale over which the concentration decreases by a factor of $e$. A function of the form $f(x) = f(0) \\exp(-x/\\lambda)$ has a characteristic length $\\lambda$.\nBy comparing our solution for $C(x)$ with this general form, we can identify the argument of the exponential:\n$$\n-\\frac{x}{\\lambda} = -\\sqrt{\\frac{k}{D}} x\n$$\nFrom this comparison, the characteristic decay length $\\lambda$ is directly derived:\n$$\n\\lambda = \\frac{1}{\\sqrt{k/D}} = \\sqrt{\\frac{D}{k}}\n$$\nThis provides the analytical expression for the characteristic decay length, derived from first principles as required. Note that the constant $A_2$ would be determined by the constant flux boundary condition at $x=0$, but its value is not necessary for finding $\\lambda$.\n\nNow, we must compute the numerical value of $\\lambda$ using the provided constants:\n$D = 10 \\text{ } \\mu\\mathrm{m}^{2}/\\mathrm{s}$\n$k = 0.001 \\text{ } \\mathrm{s}^{-1}$\n\nSubstituting these values into the expression for $\\lambda$:\n$$\n\\lambda = \\sqrt{\\frac{10 \\text{ } \\mu\\mathrm{m}^{2}/\\mathrm{s}}{0.001 \\text{ } \\mathrm{s}^{-1}}}\n$$\nThe units are consistent, as $[\\lambda] = \\sqrt{\\frac{\\mu\\mathrm{m}^{2} \\cdot \\mathrm{s}^{-1}}{\\mathrm{s}^{-1}}} = \\sqrt{\\mu\\mathrm{m}^{2}} = \\mu\\mathrm{m}$.\nWe compute the numerical value:\n$$\n\\lambda = \\sqrt{\\frac{10}{0.001}} \\text{ } \\mu\\mathrm{m} = \\sqrt{10000} \\text{ } \\mu\\mathrm{m} = 100 \\text{ } \\mu\\mathrm{m}\n$$\nThe result is exactly $100$. The problem asks for the answer to be rounded to three significant figures. The value $100$ when resulting from this calculation is precise, and can be represented as $1.00 \\times 10^2$, which has three significant figures. Therefore, the value $100$ is compliant with the requirement.", "answer": "$$\n\\boxed{100}\n$$", "id": "2683698"}]}